Company / Shareholders' Equity
GYRE THERAPEUTICS, INC. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$106.0M
FY2025
5-year range
-$15.8M / $106.0M
FY2021-FY2025
Trend
+67.5%
vs FY2024
Sector context
#169 of 213
Health Care
What the data says
GYRE THERAPEUTICS, INC.'s shareholders' equity of $106M is lower than 79% of companies in the Health Care sector (FY2025). Shareholders' Equity has fluctuated over the past 10 years, ranging from -$16M in FY2023 to $106M in FY2025.
Based on SEC 10-K filings.
$106M in FY2025 with a 5-year CAGR of +9.2%.
Improved from -$16M to $106M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +13.7%
- 5-Year CAGR
- +9.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 213This company $106.0M Sector average $2.5B
▼
-95.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +9.2%, indicating consistent growth.
- In FY2025, shareholders' equity increased 67.5% year-over-year.
- Ranks #169 out of 213 companies in the Health Care sector.
- Lowest shareholders' equity in the period was in FY2023.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $106.0M | +67.5% |
| FY2024 | $63.3M | +500.0% |
| FY2023 | -$15.8M | -121.9% |
| FY2022 | $72.2M | +75.8% |
| FY2021 | $41.1M | -39.9% |
| FY2020 | $68.3M | +0.0% |
| FY2019 | $68.3M | +122.1% |
| FY2018 | $30.8M | +0.0% |
| FY2017 | $30.8M | +91.5% |
| FY2016 | $16.1M | -48.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026